Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 711 participants.
Also called NCT01968954
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 711 participants
- Sponsor
- Registry
-
NCT01968954 -
2013-002642-37
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Czechia, Germany, Hong Kong SAR China, Italy, Poland, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01968954. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2017-05-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
- Acronym
- SPIRE-HR
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Other)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01968954- Content hash
6a38492cc181a977a73e93fe9203308ba554ed01c96c0b76ea41aba61e6ce85f